Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Photo of Larry H. Danziger

Larry H. Danziger

Professor, College of Pharmacy - Pharmacy Practice
UIC Distinguished Professor, Pharmacy Practice
Professor of Pharmacy in Medicine, College of Medicine - Medicine
Executive Director, Center for Advanced Design, Research and Exploration
Director, Section of Infectious Diseases Pharmacotherapy, Pharmacy Practice



833 South Wood, Chicago, IL

Office Phone:

(312) 996-0892 (work)

About Heading link

Larry H. Danziger, Pharm.D., is the Executive Director of Center for Advanced Research, Exploration and Design (CADRE) and a Professor of Pharmacy Practice, Professor of Pharmacy in Medicine and the Co-Director of the Section of Infectious Diseases, College of Pharmacy, Department of Pharmacy Practice, at the UIC.

Dr. Danziger has been a faculty member at UIC since 1985.He served as Chair of the UIC Human Subject IRB for five years (1995-1999). From 1999 -2008 he was the Associate Vice Chancellor for Research and from 2008 – 2010 he was the Interim Vice Chancellor for Research at the University of Illinois at Chicago. Dr. Danziger was the Co-Chair of the Campus P&T Committee in 2013.

Dr. Danziger has authored or coauthored 145 journal articles, 150 research abstracts and 22 book chapters. He is on the editorial board of the journal Diagnostic Microbiology and Infectious Diseases and Antibiotics Dr. Danziger has trained 70 post-doctoral Infectious Disease Pharmacy Fellows.

He is the recipient of the first Pharmacoeconomics Award presented by the American College of Clinical Pharmacy and the recipient of the 1999 Research Award of the Society of Infectious Pharmacy. In 2010, Dr. Danziger was named Researcher of the Year Award (honorary) for his years of service to the research mission at the University of Illinois at Chicago. In June of 2021, Dr. Danziger was the recipient of the UIC Distinguished Professor award.

Research Interests:
Dr. Danziger’s research interests include basic and clinical research regarding both new and old antimicrobials. He played a critical role in the redevelopment of paromomycin, an antibiotic originally developed in the 1950s. In collaboration between the University of Illinois at Chicago and the WHO, paromomycin was developed as a therapeutic for the treatment of visceral leishmaniasis. Paromomycin was granted orphan drug status in 2005 and was approved by the Drug Controller General of India in September 2006 for treatment of visceral leishmaniasis. Dr. Danziger is currently reevaluating the older drugs, such as Polymyxin B for expanded clinical use.

Teaching and Supervision Heading link

Concepts in Drug Development (PMPR 536), 8/21/2023 – 12/1/2023
Concepts in Drug Development (PMPR 536), 8/21/2023 – 12/1/2023
Undergrad Res Exp Pharm Pract (PMPR 300), 1/9/2023 – 4/28/2023
Drug Development and Drug Discovery (PSCI 508), 8/26/2022 – 12/8/2022
Introduction to Pharmaceutical Sciences (P200), 8/25/2022 – 12/1/2022
Pharmacy Practice Research (PMPR 380), 8/25/2022 – 12/31/2022
Undergrad Resrch Pharm Pract (PMPR 380), 1/10/2022 – 4/29/2022
Drug Develoment Drug Discovery (PSCI 508), 8/17/2020 – Present
Drug Discovery, Design and Development (PMPG 507), 8/26/2019 – 12/20/2019

Selected Grants

Illinois Manufacturing Excellence Center, IMEC., 10/1/2020 - 9/30/2024, Obligated Amount: $11874246; Anticipated Amount: $11874246

Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain, National Institutes of Health (National Center for Complementary and Integrative Health)., 9/21/2020 - 9/23/2021, Obligated Amount: $827226; Anticipated Amount: $827226

Evaluation of Needs for Small Manufacturers DEI, Illinois Manufacturing Excellence Center., 8/1/2020 - 12/31/2020, Obligated Amount: $95000; Anticipated Amount: $49000

Evaluation of Needs for Small Manufacturers DEI, Illinois Manufacturing Excellence Center., 8/1/2020 - 12/31/2020, Obligated Amount: $95000; Anticipated Amount: $49000

Advanced Manufacturing Technology (AMT) and Cybersecurity Study, Il Manufacturing Excellence Ctr., 2/1/2020 - 12/31/2020, Obligated Amount: $99456; Anticipated Amount: $99456

Illinois Manufacturing Excellence Center, Il Manufacturing Excellence Ctr., 10/1/2016 - 9/30/2020, Obligated Amount: $9752479; Anticipated Amount: $9752479

Illinois Manufacturing Excellence Center- SBIR Project, Il Manufacturing Excellence Ctr., 11/1/2015 - 12/31/2015, Obligated Amount: $20733; Anticipated Amount: $20733

Illinois Manufacturing Excellence Center, Il Manufacturing Excellence Ctr., 10/1/2015 - 9/30/2016, Obligated Amount: $2333371; Anticipated Amount: $2333371

Activity of oritavancin versus daptomycin or linezolid alone and in combination with gentamicin, rifampin or ceftriaxone against multi-drug resistant Enterococcus faecium in in vitro time-kill assays and in vivo survival assays using Galleria mellonella larvae, The Medicines Company., 5/2015 - 5/31/2017, Obligated Amount: $17500; Anticipated Amount: $17500

Selected Publications

Drwiega, Emily N, Danziger, Larry H, Burgos, Rodrigo M, Michienzi, Sarah M. (2023). Commonly Reported Mosquito-Borne Viruses in the United States: A Primer for Pharmacists.. Journal of Pharmacy Practice, 8971900231167929. doi:10.1177/08971900231167929.

Drwiega, Emily N, Griffith, Nicole C, Danziger, Larry H. (2022). Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections. Expert Opinion on Drug Metabolism & Toxicology, 18, (4), 245-259. doi:10.1080/17425255.2022.2081148.

Drwiega, Emily N, Danziger, Larry H, Johnson, Stuart, Skinner, Andrew M. (2021). 766. Readmissions of Hospitalized Patients with Clostridioides difficile Infection (CDI) for Recurrent CDI Is Common. Open Forum Infectious Diseases, 8, (Supplement_1), s480-s480. doi:10.1093/ofid/ofab466.963.

Skinner, Andrew M, Tan, Xing, Sirbu, Benjamin D, Danziger, Larry H, Gerding, Dale N, Johnson, Stuart. (2021). A Tapered-Pulsed Fidaxomicin Regimen following Treatment in Patients with Multiple Clostridioides difficile Infection Recurrences. Clinical Infectious Diseases, 73, (6), ciab233-. doi:10.1093/cid/ciab233.

Tan, Xing, Skinner, Andrew M, Sirbu, Benjamin, Danziger, Larry H, Gerding, Dale N, Johnson, Stuart, Johnson, Stuart. (2020). 797. Management of Patients with Multiple Clostridioides difficile Infection Recurrences using a Tapered-Pulsed Fidaxomicin Strategy. Open Forum Infectious Diseases, 7, (Suppl 1), s441-s442. doi:10.1093/ofid/ofaa439.987.

Butler, David A, Biagi, Mark, Gupta, Vikas, Wieczorkiewicz, Sarah, Young, Lisa, Patel, Ursula, Naegele, Sandy, Santarossa, Maressa, Harrington, Amanda, Postelnick, Mike, Suseno, Mira, Christensen, Alyssa, Giddens, Julie, Murrey, Tim, Hanson, Amy, Sam, Sharon, Pettit, Natasha, Danziger, Larry, Wenzler, Eric. (2020). Development of a 51-hospital Chicagoland regional antibiogram and comparison to local hospital and national surveillance data. Infection Control and Hospital Epidemiology, 41, (12), 1409-1418. doi:10.1017/ice.2020.334.

Schriever, Christopher A, Danziger, Larry H. (2020). Recurrent Clostridioides difficile Infections: Should We Respond More to Toxin B?. Clinical Infectious Diseases, 71, (1), 87-88. doi:10.1093/cid/ciz814.

Wenzler, E, Meyer, KM, Bleasdale, SC, Sikka, M, Mendes, RE, Bunnell, KL, Finnemeyer, M, Rosenkranz, SL, Danziger, LH, Rodvold, KA. (2020). Ex Vivo Urinary Bactericidal Activity and Urinary Pharmacodynamics of Fosfomycin after Two Repeated Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 64, (2), e02102-e02119. doi:10.1128/aac.02102-19.

Tan, Xing, Danziger, Larry H, Gerding, Dale N. (2019). 1496. Bezlotoxumab Administered at the End of a Suppressive Drug Regimen for Patients with Multiply Recurrent Clostridioides difficile Infection. Open Forum Infectious Diseases, 6, (Supplement_2), s545-s545. doi:10.1093/ofid/ofz360.1360.

Professional Leadership

IDPH COVID-19 Pharmacy Vaccine Taskforce, State of Illinois, 1/4/2021 - Present

Governance Committee of Board of Directors, IMEC, 1/1/2016 - Present

Notable Honors

2021, UIC Distinguished Professor, UIC Distinguished Professor

2016, Jeff King Professor Lectureship, UC Davis Health System


Doctor of Pharmacy, University of Cincinnati Medical Center, United States, 1978
Bachelor of Science, University of Illinois at Chicago, United States, 1976
Bachelor of Arts, University of Illinois at Urbana Champaign, United States, 1973

Postgraduate Training:
Pharmacy Resident, Cincinnati Veterans Hospital, United States, 1978